Hospital Infection Therapeutics Market (Therapeutics: Anti-bacterial Drugs, Anti-fungal Drugs, Anti-viral Drugs, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2031

Hospital Infection Therapeutics Market (Therapeutics: Anti-bacterial Drugs, Anti-fungal Drugs, Anti-viral Drugs, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2031


Hospital Infection Therapeutics Market – Scope of Report

TMR’s report on the global hospital infection therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global hospital infection therapeutics market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global hospital infection therapeutics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the hospital infection therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global hospital infection therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global hospital infection therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global hospital infection therapeutics market.

The report delves into the competitive landscape of the global hospital infection therapeutics market. Key players operating in the global hospital infection therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global hospital infection therapeutics market profiled in this report.

Key Questions Answered in Global hospital infection therapeutics Market Report
  • What is the sales/revenue generated by hospital infection therapeutics across all regions during the forecast period?
  • What are the opportunities in the global hospital infection therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Hospital Infection Therapeutics Market – Research Objectives and Research Approach

The comprehensive report on the global hospital infection therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global hospital infection therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global hospital infection therapeutics market.


1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Hospital Infection Therapeutics Market
4. Market Overview
4.1. Market Segmentation
  4.1.1. Segment Definition
  4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
  4.3.1. Drivers
  4.3.2. Restraints
  4.3.3. Opportunities
4.4. Global Hospital Infection Therapeutics Market Analysis and Forecast, 2023-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Disease Prevalence & Incidence Rate Globally With Key Countries
5.3. COVID-19 Pandemic Impact on Industry
6. Hospital Infection Therapeutics Market Analysis and Forecast, by Therapeutics
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Therapeutics, 2017–2031
  6.3.1. Anti-bacterial Drugs
  6.3.2. Anti-fungal Drugs
  6.3.3. Anti-viral Drugs
  6.3.4. Others
6.4. Market Attractiveness, by Therapeutics
7. Global Hospital Infection Therapeutics Market Analysis and Forecast, by Infection
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Infection, 2017–2031
  7.3.1. Hospital Acquired Pneumonia
  7.3.2. Urinary Tract Infections
  7.3.3. Gastrointestinal Disorders
  7.3.4. Bloodstream Infections
  7.3.5. Surgical Site Infections
  7.3.6. Other Hospital Infections
7.4. Market Attractiveness, by Infection
8. Global Hospital Infection Therapeutics Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2017–2031
  8.2.1. North America
  8.2.2. Europe
  8.2.3. Asia Pacific
  8.2.4. Latin America
  8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
9. North America Hospital Infection Therapeutics Market Analysis and Forecast
9.1. Introduction
  9.1.1. Key Findings
9.2. Market Value Forecast, by Therapeutics, 2023–2031
  9.2.1. Anti-bacterial Drugs
  9.2.2. Anti-fungal Drugs
  9.2.3. Anti-viral Drugs
  9.2.4. Others
9.3. Market Value Forecast, by Infection, 2023–2031
  9.3.1. Hospital Acquired Pneumonia
  9.3.2. Urinary Tract Infections
  9.3.3. Gastrointestinal Disorders
  9.3.4. Bloodstream Infections
  9.3.5. Surgical Site Infections
  9.3.6. Other Hospital Infections
9.4. Market Value Forecast, by Country, 2023–2031
  9.4.1. U.S.
  9.4.2. Canada
9.5. Market Attractiveness Analysis
  9.5.1. By Therapeutics
  9.5.2. By Infection
  9.5.3. By Country
10. Europe Hospital Infection Therapeutics Market Analysis and Forecast
10.1. Introduction
  10.1.1. Key Findings
10.2. Market Value Forecast, by Therapeutics, 2023–2031
  10.2.1. Anti-bacterial Drugs
  10.2.2. Anti-fungal Drugs
  10.2.3. Anti-viral Drugs
  10.2.4. Others
10.3. Market Value Forecast, by Infection, 2023–2031
  10.3.1. Hospital Acquired Pneumonia
  10.3.2. Urinary Tract Infections
  10.3.3. Gastrointestinal Disorders
  10.3.4. Bloodstream Infections
  10.3.5. Surgical Site Infections
  10.3.6. Other Hospital Infections
10.4. Market Value Forecast, by Country/Sub-region, 2023–2031
  10.4.1. Germany
  10.4.2. U.K.
  10.4.3. France
  10.4.4. Italy
  10.4.5. Spain
  10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
  10.5.1. By Therapeutics
  10.5.2. By Infection
  10.5.3. By Country/Sub-region
11. Asia Pacific Hospital Infection Therapeutics Market Analysis and Forecast
11.1. Introduction
  11.1.1. Key Findings
11.2. Market Value Forecast, by Therapeutics, 2023–2031
  11.2.1. Anti-bacterial Drugs
  11.2.2. Anti-fungal Drugs
  11.2.3. Anti-viral Drugs
  11.2.4. Others
11.3. Market Value Forecast, by Infection, 2023–2031
  11.3.1. Hospital Acquired Pneumonia
  11.3.2. Urinary Tract Infections
  11.3.3. Gastrointestinal Disorders
  11.3.4. Bloodstream Infections
  11.3.5. Surgical Site Infections
  11.3.6. Other Hospital Infections
11.4. Market Value Forecast, by Country/Sub-region, 2023–2031
  11.4.1. China
  11.4.2. Japan
  11.4.3. India
  11.4.4. Australia & New Zealand
  11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
  11.5.1. By Therapeutics
  11.5.2. By Infection
  11.5.3. By Country/Sub-region
12. Latin America Hospital Infection Therapeutics Market Analysis and Forecast
12.1. Introduction
  12.1.1. Key Findings
12.2. Market Value Forecast, by Therapeutics, 2023–2031
  12.2.1. Anti-bacterial Drugs
  12.2.2. Anti-fungal Drugs
  12.2.3. Anti-viral Drugs
  12.2.4. Others
12.3. Market Value Forecast, by Infection, 2023–2031
  12.3.1. Hospital Acquired Pneumonia
  12.3.2. Urinary Tract Infections
  12.3.3. Gastrointestinal Disorders
  12.3.4. Bloodstream Infections
  12.3.5. Surgical Site Infections
  12.3.6. Other Hospital Infections
12.4. Market Value Forecast, by Country/Sub-region, 2023–2031
  12.4.1. Brazil
  12.4.2. Mexico
  12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
  12.5.1. By Therapeutics
  12.5.2. By Infection
  12.5.3. By Country/Sub-region
13. Middle East & Africa Hospital Infection Therapeutics Market Analysis and Forecast
13.1. Introduction
  13.1.1. Key Findings
13.2. Market Value Forecast, by Therapeutics, 2023–2031
  13.2.1. Anti-bacterial Drugs
  13.2.2. Anti-fungal Drugs
  13.2.3. Anti-viral Drugs
  13.2.4. Others
13.3. Market Value Forecast, by Infection, 2023–2031
  13.3.1. Hospital Acquired Pneumonia
  13.3.2. Urinary Tract Infections
  13.3.3. Gastrointestinal Disorders
  13.3.4. Bloodstream Infections
  13.3.5. Surgical Site Infections
  13.3.6. Other Hospital Infections
13.4. Market Value Forecast, by Country/Sub-region, 2023–2031
  13.4.1. GCC Countries
  13.4.2. South Africa
  13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
  13.5.1. By Therapeutics
  13.5.2. By Infection
  13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
  14.3.1. Merck & Co., Inc.
14.3.1.1. Company Revenue
14.3.1.2. Business Overview
14.3.1.3. Product Segments
14.3.1.4. Geographic Footprint
14.3.1.5. Production Capacity/Plant Details, etc. (*As Applicable)
14.3.1.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
  14.3.2. Pfizer, Inc.
14.3.2.1. Company Revenue
14.3.2.2. Business Overview
14.3.2.3. Product Segments
14.3.2.4. Geographic Footprint
14.3.2.5. Production Capacity/Plant Details, etc. (*As Applicable)
14.3.2.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
  14.3.3. GlaxoSmithKline plc
14.3.3.1. Company Revenue
14.3.3.2. Business Overview
14.3.3.3. Product Segments
14.3.3.4. Geographic Footprint
14.3.3.5. Production Capacity/Plant Details, etc. (*As Applicable)
14.3.3.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
  14.3.4. AstraZeneca
14.3.4.1. Company Revenue
14.3.4.2. Business Overview
14.3.4.3. Product Segments
14.3.4.4. Geographic Footprint
14.3.4.5. Production Capacity/Plant Details, etc. (*As Applicable)
14.3.4.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
  14.3.5. Johnson & Johnson Services, Inc.
14.3.5.1. Company Revenue
14.3.5.2. Business Overview
14.3.5.3. Product Segments
14.3.5.4. Geographic Footprint
14.3.5.5. Production Capacity/Plant Details, etc. (*As Applicable)
14.3.5.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
  14.3.6. F. Hoffmann-La Roche Ltd.
14.3.6.1. Company Revenue
14.3.6.2. Business Overview
14.3.6.3. Product Segments
14.3.6.4. Geographic Footprint
14.3.6.5. Production Capacity/Plant Details, etc. (*As Applicable)
14.3.6.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
  14.3.7. Bayer AG
14.3.7.1. Company Revenue
14.3.7.2. Business Overview
14.3.7.3. Product Segments
14.3.7.4. Geographic Footprint
14.3.7.5. Production Capacity/Plant Details, etc. (*As Applicable)
14.3.7.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
  14.3.8. Allergan plc.
14.3.8.1. Company Revenue
14.3.8.2. Business Overview
14.3.8.3. Product Segments
14.3.8.4. Geographic Footprint
14.3.8.5. Production Capacity/Plant Details, etc. (*As Applicable)
14.3.8.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
  14.3.9. Sanofi S.A.
14.3.9.1. Company Revenue
14.3.9.2. Business Overview
14.3.9.3. Product Segments
14.3.9.4. Geographic Footprint
14.3.9.5. Production Capacity/Plant Details, etc. (*As Applicable)
14.3.9.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
  14.3.10. Gilead Sciences, Inc.
14.3.10.1. Company Revenue
14.3.10.2. Business Overview
14.3.10.3. Product Segments
14.3.10.4. Geographic Footprint
14.3.10.5. Production Capacity/Plant Details, etc. (*As Applicable)
14.3.10.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
  14.3.11. Basilea Pharmaceutica Ltd.
14.3.11.1. Company Revenue
14.3.11.2. Business Overview
14.3.11.3. Product Segments
14.3.11.4. Geographic Footprint
14.3.11.5. Production Capacity/Plant Details, etc. (*As Applicable)
14.3.11.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
  14.3.12. Bristol-Myers Squibb Company
14.3.12.1. Company Revenue
14.3.12.2. Business Overview
14.3.12.3. Product Segments
14.3.12.4. Geographic Footprint
14.3.12.5. Production Capacity/Plant Details, etc. (*As Applicable)
14.3.12.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings